CVS Health Q2 2026 GAAP EPS $2.31, adj EPS $2.58; raises FY guidance to $7.90-$8.10 adj EPS

CVS HEALTH Corp

2026-Q2 EPS reported $4.61 revenue$206,522,000,000

Total revenues $106.1B, up 7.3% YoY; GAAP diluted EPS $2.31 vs $0.80 prior year.
Adjusted EPS $2.58 vs $1.81 prior year; Health Care Benefits MBR improved to 87.4% from 89.9%.
Full-year 2026 guidance raised: GAAP EPS $6.84-$7.04 (from $6.24-$6.44), adj EPS $7.90-$8.10 (from $7.30-$7.50).
Cash flow from operations guidance raised to at least $11.5B from at least $9.5B; YTD cash flow $10.6B.
Health Services segment revenue up 11.5% to $51.8B; Pharmacy & Consumer Wellness prescriptions filled up 4.3%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.